CIPLA Q2 FY27 Earnings Call: Reiterates $1 Billion US Exit Run-Rate, One India Posts Record Revenue

CIPLA held its Q2 FY27 earnings call on October 27, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Broad-Based Quarter with Margin Expansion in Line with Guidance

• Revenue of Rs.7,404 crore, up 4% QoQ — broad-based performance across key businesses; One India posted its highest-ever quarterly revenue in Q2 FY 2026-2027.
• EBITDA margin (ex-other income) at 18.7%, up 200 bps QoQ — in line with guidance; gross margin after material costs at 64.4%, up 7% QoQ, supported largely by improved product mix.
• PAT of Rs.878 crore (11.9% of sales), up 77 bps QoQ — effective tax rate at 27.2% for the quarter; FY 2026-2027 full-year ETR guided at 27-27.5% vs 27% reported in H1 FY 2026-2027.
• Total expenses of Rs.3,382 crore, up 4% QoQ — CFO Dinesh Jain said there was no one-off; Q2 expense base is normally higher than Q1, with launch investments underway ahead of revenue ramp-up.
• Net cash equivalent balance of Rs.9,823 crore as of 30 September 2026, with debt including lease liabilities at Rs.699 crore, supported by free cash generation.

One India Sustains Double-Digit Streak; GLP-1 Concentration Questioned

• One India grew 12% YoY in Q2 FY 2026-2027 — branded prescription grew 15% per IQVIA YTD September 2026, led by respiratory (11%), anti-diabetes (50%, including GLP), urology (11%) and dermatology (16%); chronic mix at 60.3% (IQVIA MAT September 2026).
• India business grew 14.6% vs the market's 14.3% on an H1 FY 2026-2027 basis — CEO Achin Gupta countered Goldman Sachs' concern on semaglutide reliance (GLP portfolio ~10% of domestic sales), citing market-beating performance in respiratory and, excluding GLPs, diabetic, cardiac and dermatology therapies.
• GLP-1 portfolio at ~10% of domestic sales, led by tirzepatide — "Your Peak" is the second largest brand in GLP rankings; management sees 5-10% month-on-month growth with no saturation expected, but gave no specific FY 2027-2028 growth number or semaglutide launch timeline.
• Consumer business grew at a high single-digit rate in Q2/H1 FY 2026-2027 — all consumer brands gained share and held category leadership; headwinds from costs and pricing are being worked on for mitigation; management expects good double-digit growth going forward (period unspecified).
• Trade generics grew strong double-digit QoQ but mid-single-digit YoY vs Q2 FY 2025-2026 due to seasonality and cost factors; management expects steady growth consistent with past years without specifying the normalized quarterly run rate.
• Q2 launches included Gravismart, Galvus DM and SR, Diatore and Ryzontem — trade generics added 15+ new launches in Q2 FY 2026-2027; Cipla continues to lead the IPM in volume share.

$1B Exit Run-Rate Reiterated; H2 Hinges on Approvals and Ramp-Up

• US revenue of $172 million in Q2 FY 2026-2027, up $10 million sequentially — guidance maintained to exit FY 2026-2027 at a ~$1 billion annualized run rate (bridging, per the analyst's framing, from ~$170mn to ~$250mn quarterly levels), with an $80 million ramp-up expected in H2 FY 2026-2027.
• Two key US respiratory approvals secured in FY 2026-2027 — generic Ventolin in Q1 FY 2026-2027 and generic Advair in Q2 FY 2026-2027 (approved July 2026), the latter Cipla's first DPI approval from its US-based manufacturing network; Advair launches in Q3 FY 2026-2027 with a couple of months' delay vs the normal timeline as the first DPI from the newly set-up US plant.
• Three significant launches remain for H2 FY 2026-2027 — two respiratory assets and one key peptide opportunity (including the Symbicort inhaler); exact approval dates are not 100% in the company's control and depend on how the FDA reviews the files.
• Ventolin flagged as a very big opportunity — by itself covers much of the delta to the targeted exit rate; H2-weighted ramp reflects supply scale-up from the new North America site, not contract renewals or winter seasonality; share still in single digits per the analyst.
• Albuterol MDI share at 22% (IQVIA, last week of September 2026) — #1 position in the US market of ~24 million units where Cipla is the only generic; management expects an "exponential" supply increase by H2 FY 2026-2027 rather than a 2x-4x step-up.
• Lanreotide not anticipated to return in FY 2026-2027 — two parallel paths: working with Pharmathen on remediation and re-representation to the FDA, and filing from a new North America site; neither path is included in the $1 billion FY 2026-2027 exit run-rate guidance.
• Symbicort seen as a "pretty big contribution" — respiratory is a complex, fewer-player market per FDA classification; confidence is conditional on competitive dynamics not changing dramatically by the time Cipla enters; management declined to disclose product goal dates or prior CRLs.

Complex-Asset Filings Step-Up; Oncology In-Licensing Builds

• 45-50 complex-asset filings targeted for North America over the next 3 years (FY 2027-2028 to FY 2029-2030) — versus a historical average of ~10 filings; the pipeline contains no plain-vanilla generics.
• 4 biosimilar assets under development for global markets — management noted a general acceptance that most US biosimilars will get a phase 3 waiver; for the lead product, Cipla has an understanding via FDA consultation that phase 3 would not be needed; 1-2 assets to be added each year with selective in-licensing (e.g. Pembro).
• Keytruda biosimilar filing expected in FY 2027-2028 — positioning Cipla to launch in time for Keytruda's patent expiry around calendar 2029; management reiterated its aim to be in the first wave of launches, with Cipla's own teams involved in the US filing.
• Exclusive licensing agreement signed with CTCQ (Sino Biopharm Group) — for a novel HER2 bispecific antibody-drug conjugate; a separate exclusive partnership with Qilu Pharmaceuticals covers US commercialization of a pembrolizumab biosimilar, expected to be among the first wave of launches (no launch timeline provided).
• Biosimilar manufacturing sits in the Aspergen JV with Chemwell — Cipla holds majority ownership; the JV has access to a facility and is scaling up.
• R&D spend of Rs.423 crore (5.7% of revenue) in Q2 FY 2026-2027 — full-year FY 2026-2027 guidance maintained at 6-7% of revenue; FY 2027-2028 guidance to come with next year's numbers.
• Cash deployment skewed to North America or Europe — CFO said Cipla will pursue selective acquisitions of complex or differentiated assets, as the number-one player by volume in India finds non-overlapping Indian assets harder to source.

SA Tender Ruling in Cipla's Favour; Pithampur Still Under OAI

• South Africa private market secondary growth of 6.5% vs market growth of 5% (IQVIA MAT August 2026) — but primary data suggests a decline, attributed to an accounting change disclosed last quarter and a lost tender contested in courts; a favorable court ruling came out a few days back and management hopes the tender business will correct now.
• Tender exposure concentrated in South Africa — management said the tender-driven share of the emerging markets/Europe business is "not that high" and was not quantified.
• EMEU revenue of $101 million in Q2 FY 2026-2027 — amid a challenging geopolitical environment and market-specific headwinds; resilience supported by strong execution and cost discipline across GTM and B2B segments.
• USFDA classified the Invagen Unit 3 (New York) inspection as VAI in Q2 FY 2026-2027 — a routine GMP inspection at Invagen Long Island in October 2026 (Q3 FY 2026-2027) concluded with 0 Form 483 observations.
• Pithampur (Indore) follow-up inspection drew 7 Form 483 observations in Q2 FY 2026-2027 — the site received an OAI ~3.5 years ago; management noted no repeats and no data integrity issues this time and remains committed to getting the site out of OAI status; conversion to BAI would open further opportunities. Risk mitigation is in place, with new approvals coming from the US site or Goa.

Sequential Margin Improvement Guided; FY28 Outlook Deferred

• FY 2026-2027 EBITDA margin guidance of 18.5-20% reaffirmed — CFO Dinesh Jain expects sequential margin improvement over Q3 and Q4 FY 2026-2027, driven by the US business ramp-up, even though Q4 margins historically trend lower on seasonality.
• US exit run rate of $1 billion for FY 2026-2027 reiterated by the CFO — multiple pathways exist via ramp-up of already-approved assets and new assets, with the exact mix dependent on when approvals come through; management declined to attribute the delta to specific products.
• No FY 2027-2028 margin outlook was given on this call — guidance for FY 2027-2028 will be provided by the start of that fiscal year.
• India priorities for FY 2026-2027 — sustain growth momentum and outperform the market in branded prescription, trade generics and consumer wellness; build presence in chronic therapies beyond respiratory (cardio, metabolic including obesity, dermatology, urology) to reduce seasonality.
• Segment-level EBITDA split not disclosed — CFO declined to confirm whether India contributes more than 55-60% of EBITDA, noting Cipla does not report segment-wise profitability; he noted much R&D is directed toward developed markets, so a North America revenue swing impacts North America EBITDA more than India's.
• Oncology trade margin cap announced by the government — management believes it will benefit patients and have no significant impact on Cipla's business; impact of further outcomes will be assessed only once the directive is issued.